Microglia Control Neuronal Network Excitability via BDNF Signalling by Francesco, Ferrini & Yves, De Koninck
Hindawi Publishing Corporation
Neural Plasticity
Volume 2013, Article ID 429815, 11 pages
http://dx.doi.org/10.1155/2013/429815
Review Article
Microglia Control Neuronal Network Excitability
via BDNF Signalling
Francesco Ferrini1 and Yves De Koninck2,3
1 Department of Veterinary Sciences, University of Turin, Grugliasco, 10095 Turin, Italy
2 Institut Universitaire en Sante´ Mentale de Que´bec, Que´bec, QC, Canada G1J 2G3
3Department of Psychiatry and Neuroscience, Universite´ Laval, Que´bec, QC, Canada G13 7P4
Correspondence should be addressed to Yves De Koninck; yves.dekoninck@neuro.ulaval.ca
Received 8 June 2013; Accepted 28 July 2013
Academic Editor: Long-Jun Wu
Copyright © 2013 F. Ferrini and Y. De Koninck.This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Microglia-neuron interactions play a crucial role in several neurological disorders characterized by altered neural network
excitability, such as epilepsy and neuropathic pain. While a series of potential messengers have been postulated as substrates of the
communication between microglia and neurons, including cytokines, purines, prostaglandins, and nitric oxide, the specific links
betweenmessengers, microglia, neuronal networks, and diseases have remained elusive. Brain-derived neurotrophic factor (BDNF)
released bymicroglia emerges as an exception in this riddle. Here, we review the current knowledge on the role played bymicroglial
BDNF in controlling neuronal excitability by causing disinhibition.The efforts made by different laboratories during the last decade
have collectively provided a robust mechanistic paradigm which elucidates the mechanisms involved in the synthesis and release of
BDNF frommicroglia, the downstream TrkB-mediated signals in neurons, and the biophysical mechanism by which disinhibition
occurs, via the downregulation of the K+-Cl− cotransporter KCC2, dysrupting Cl− homeostasis, and hence the strength of GABAA-
and glycine receptor-mediated inhibition.The resulting altered network activity appears to explain several features of the associated
pathologies. Targeting the molecular players involved in this canonical signaling pathway may lead to novel therapeutic approach
for ameliorating a wide array of neural dysfunctions.
1. Introduction
Once simply considered as the “guardians” of the cen-
tral nervous system (CNS), microglia have more recently
emerged as key players in regulating neuronal network
excitability. Indeed, physical and chemical alterations in
the extracellular environment promote the synthesis and
release of several microglia-derived molecules which, in
turn, shape neuronal circuit function. The effects of such
microglia-neuron interactions were found to be critical in
the course of different central disorders, and in particular
seminal studies provided significant evidence for a role of
microglia in the pathogenesis of seizures (for review see
[1, 2]) which was associated with increased glutamatergic
transmission through the potentiation of NMDA receptor-
mediated activity [3]. However, from a theoretical point of
view, raising network excitability can be equally achieved
through increasing excitatory inputs or removing inhibitory
ones. In fact, unmasking silent interconnections can be better
achieved through disinhibition than enhanced excitation.
Furthermore, disinhibition has been shown as an upstream
substrate of activity-dependent enhancement of excitation in
several plasticity paradigms [4–7]. Thus, in addition to the
glutamatergic hypothesis, it can be postulated that microglia
alter neuronal excitability by affecting synaptic inhibition.
This hypothesis has been explored during the last decade and
the results of several investigations have uncoveredmolecular
mechanisms underlying microglia-mediated disinhibition.
Synaptic inhibition in central neurons is mediated by 𝛾-
amino-butyric acid (GABA) and glycine (Gly) which activate
ionic channels (GABAAR and GlyR) permeable to anions,
namely, chloride (Cl−) and bicarbonate (HCO
3
−). Under
physiological conditions, Cl− flows inwardly andHCO
3
− out-
wardly, along with their electrochemical gradient. Cl− contri-
bution is by far the more conspicuous, and, consequently, the
reversal potential of GABA/glycine (EGABA/Egly) in adult
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neurons is set below the resting potential (Vr) near the Cl−
equilibrium (ECl). It follows that when GABAAR/GlyR are
activated, Cl− produces a net hyperpolarization. Although in
principle correct, this brief summary of the ionicmechanisms
of synaptic inhibition provides a quite static representation of
GABA/Gly-mediated transmission and importantly does not
take into account that, EGABA/EGly and Vr being only few
millivolts apart, even a small change in anion concentrations
may have a profound functional impact [8, 9]. In this respect,
the critical variable is represented by the intracellular Cl−
concentration and the critical property is the capacity of
the cell to maintain this concentration low. In the event
that intracellular Cl− rises, it follows that (i) EGABA/EGly
shifts toward or beyond Vr; (ii) the Cl− gradient across
the membrane collapses; and (iii) the previously negligible
depolarizing HCO
3
− current becomes more relevant. On
the whole, an increase in the intracellular Cl− concentration
weakens the strength of GABA/Gly-mediated inhibition or,
in the extreme case, turns it into paradoxical excitation [10].
How do neurons control intracellular Cl− concentration?
Chloride homeostasis in cells is maintained by a group of
membrane carriers known as cation-chloride cotransporters
(CCCs [11, 12]). The K+-Cl− cotransporter 2, KCC2, is the
main CCC isoform expressed in central neurons [13, 14].
KCC2 extrudes Cl− following the K+ gradient, and its activity
typically maintains a low intracellular Cl− concentration,
which is the prerequisite for an effectiveGABA/Gly-mediated
inhibition. Now, KCC2 activity is not static, but it can be pro-
foundly modulated by different physiological or pathological
challenges. The most spectacular example of such plasticity
has been extensively described during development [14–
16]. KCC2 is little expressed in prenatal and early postnatal
brains, but during maturation it undergoes a developmental
increase, which parallels the switch in GABA/Gly-mediated
transmission from excitatory to inhibitory [14]. These mech-
anisms are thought not only to play a pivotal role in the
activity-dependent development of central synapses during
CNS maturation [17] but also to favor a proper wiring by
triggering spontaneous rhythmic activity in motor networks
[18] and to promote synaptic integration of new born neurons
in those area of the brain in which adult neurogenesis occurs
[19, 20]. On the other hand, reduction of KCC2 activity
has been associated with several neurological diseases and
conditions, originally epilepsy and neuropathic pain [10],
and more recently motor spasticity [21], stress [22], and
schizophrenia [23, 24]. Several lines of evidence accumulated
during the last decade have indeed demonstrated that the
increase in excitability in these pathological conditions can
be largely explained by a loss of inhibition, and KCC2 has
been recognized as a keymolecular target underlying this loss
[25, 26].
The findings in recent years that KCC2 can be dynam-
ically modulated by several intercellular signaling pathways
have been particularly interesting [4], the most prevalent
being brain-derived neurotrophic factor (BDNF) signaling
onto neuronal TrkB receptors [27–31]. Even more intriguing
is the finding that, in certain conditions, BDNF in the CNS is
not only released by neurons but also bymicroglia [32]. In this
review we summarize and discuss the more relevant findings
supporting the role of microglia in conditioning KCC2 func-
tion, as well as consequently inhibitory neurotransmission,
through the release of BDNF. Several convergent findings
uncover a canonical signaling mechanism by which the
immune system can control neuronal network excitability by
regulating the strength of inhibition.
2. Role of BDNF in the Control of
KCC2 Function
BDNF is a neurotrophin with important functions in neu-
ronal survival and differentiation. However, beyond its clas-
sical neurotrophic role, BDNF is directly involved in the
control of neuronal activity and synaptic plasticity as a neuro-
modulator [33–35]. These functions are described in several
areas of the CNS, such as hippocampus [36], cortex [37],
amygdala [38], cerebellum [39], and spinal cord [34], and are
involved in different forms of plasticity [40, 41]. Although
initial studies mainly focused on glutamatergic synapses,
the effects of BDNF on GABAergic transmission have lately
received increasing attention [40]. Interestingly, early work
on these effects performed in the rat hippocampus yielded
a number of conflicting results, unveiling a more complex
picture than expected. Indeed, in juvenile rodents BDNF
was found to favor a substantial depression of GABAergic
transmission via either pre- or postsynaptic mechanisms
[42, 43]; conversely, studies in immature neurons showed
an overall potentiating effect [44, 45]. To explain such a
discrepancy, it was hypothesized that the effect of BDNF onto
GABAergic transmission in hippocampal neurons might be
developmentally regulated in parallel with the switch in
GABAergic transmission from excitatory to inhibitory [46].
Thus, BDNF depresses GABAergic transmission in mature
neuronswhenGABA is inhibitory andpotentiates it in imma-
ture neurons when GABA is depolarizing, favoring activity-
dependent synapse formation which has been relayed to
GABA-mediated Ca2+ entry in developing neurons [37, 44,
46]. The fact that the changes in BDNF effects on GABA-
mediated transmission are coincident with the developmen-
tal switch in GABAergic current polarity raised the question
of whether BDNF has an effect on KCC2 function and/or
expression. This was indeed demonstrated by Rivera and
colleagues [29, 30]. The authors provided evidence that,
in hippocampal slices, BDNF rapidly downregulates KCC2
expression through the BDNF preferred receptor TrkB (tyro-
sine kinase B receptor), thus reducing neuronal Cl− extrusion
capacity [29].The effect required the activation of two down-
stream cascades involving src homology 2 domain containing
transforming protein/FGF receptor substrate 2 (Shc/FRS-2)
and phospholipase C 𝛾- (PLC𝛾-) cAMP response element-
binding protein signaling, respectively [30]. Interestingly,
the activation of the Shc pathway alone was surprisingly
found to promote the upregulation of KCC2, which might
elegantly explain the opposite effects of BDNF across brain
development based on the specific intracellular pathways
involved [30]. One important point of this study is that the
membrane level of KCC2 undergoes a fast turnover rate, and
this turnover is accelerated by exogenous BDNF or by an
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increased neuronal activity during which BDNF is released
[30]. A logical consequence is that such a fast regulation
of KCC2 activity, which happens in few hours or less, is
not compatible with the physiological time course required
for altering gene expression, and a number of alternative
mechanistic models have been proposed including protein
phosphorylation, trafficking, and quaternary structure [47].
In particular, KCC2 activity and membrane localization
seem to depend on the tyrosine phosphorylation level, and
BDNF has been shown to promote KCC2 dephosphoryla-
tion, which in turn reduces surface protein expression [48].
Thus, KCC2 phosphorylation influences protein trafficking
by either increasing endocytosis or reducing insertion [48].
Alternatively, KCC2 transport activity has been directly
correlated with the capacity of the protein to form oligomers
at the membrane level [49]. Thus, Cl− extrusion capacity is
improved if KCC2 is organized in oligomers, and an increased
oligomers/monomers ratio parallels the KCC2 upregulation
during development [49]. Interestingly, KCC2 clustering is
strongly reduced in the presence of a point mutation on the
KCC2 tyrosine phosphorylation site, suggesting that phos-
phorylation and oligomerization might simply be different
parts of the same process controlling the transporter activity
[50]. Finally, KCC2 activity can also be rapidly affected by
the activation of the Ca2+-dependent protease calpain [11],
and these pathways may be under the control of BDNF/TrkB
signaling [51].
Altogether, these findings provided clear evidence that
Cl− homeostasis can be rapidly regulated by an extracellular
signal, such as BDNF, thus inducing short- or long-term
changes in neuronal activity that cannot be simply explained
in terms of classical synaptic plasticity but rather as a novel
form of “ionic plasticity” [16].
After the initial studies on the effects of BDNF on Cl−
homeostasis in CA1 pyramidal neuron of the hippocampus
[29, 30], similar mechanisms were subsequently observed in
different regions across the CNS, including the spinal dorsal
horn [27] and ventral horn [21], the ventral tegmental area
[52], the cortex [53, 54], and the cerebellum [39]. These
findings attracted attention to the fact that BDNF may play
a pivotal role as a regulator of neuronal Cl− homeostasis in
the brain and, by ricochet, of inhibition and hence neuronal
network excitability.
3. Microglia Are a Central Source of BDNF
The expression of BDNF in synaptic vesicles and its synaptic
release from different neuronal populations [34, 55] sup-
port the role of the neurotrophin in activity-dependent
downregulation of KCC2 [30]. However, BDNF is not only
expressed by neurons but is also found in astrocytes [56]
and microglia [32]. Microglial BDNF was first shown in
microglia cultures [57, 58] and soon confirmed in different
regions of the CNS during the course of various neurological
disorders, such as viral encephalitis [59], traumatic injury
[60, 61], ischemia [62], multiple sclerosis [63], Parkinson’s
disease [64], neuropathic pain [27], and spasticity [21]. That
microglia are a potential source of BDNF is a crucial point to
predict the role of the neurotrophin in neurological disorders.
Indeed, microglia primary function is to sense and react
to alterations of the extracellular milieu with a protective
and defensive role. In the presence of factors signaling
potentially harmful, microglia undergo morphological and
functional alterations collectively identified under the term
of “microglia activation,” and, depending on the signaling
pathways involved, this process may lead to secretion of
specificmessengers, including BDNF [65]. Once released, the
neurotrophin in turn sculpts neuronal circuit excitability via
the signaling cascade described above.
The synthesis and release of BDNF in microglia appear
to be tightly associated with the purinergic receptor P2X4R
[65–67]. Purinergic receptors are endogenously activated by
ATP (Adenosine-5󸀠-triphosphate), which is typically stored
in the cytoplasm of neuronal and nonneuronal cells and
released in the extracellular space following tissue damage
[68]. Alternatively, ATP may be released by neurons [69]
or astrocytes [70]. Microglia sense extracellular ATP trough
different types of purinergic receptors [68], such as P2Y12Rs,
which can detect tiny gradient of extracellular ATP and
promote microglia migration [71, 72], or P2X7Rs, which
trigger morphological changes in microglia from a resting
to an activated state [73]. Microglial P2X4Rs, instead, do
not appear to be involved in the morphological alterations
leading to the activated phenotype, but rather their involve-
ment is a functional consequence ofmicroglia activation [65].
Indeed, P2X4Rs are normally expressed at negligible levels
in resting microglia, and they need to be upregulated to
promote BDNF synthesis and release [65]. Which external
factors are involved in the upregulation of P2X4R in activated
microglia is still a matter of debate. Chemokines released
from injured neurons, such as CCL2 and CCL21, have been
regarded as potential inductors of P2X4R expression [74,
75]. In particular, CCL21 application in vivo and in vitro
strongly promoted P2X4R upregulation in spinal microglia
[74]. Interestingly, in both CCL21 [74] and P2X4R [65] defi-
cient mice microglia activation is not compromised, which
implies a mechanistic separation between the morphological
changes and the subsequent downstream effects. Also CCL2,
which instead plays an important role in microglia activation
after injury [76, 77], has been suggested to participate in
the P2X4R upregulation process; however, CCL2 does not
seem involved in de novo expression of the protein, but
rather it has been suggested to promote P2X4R trafficking
from intracellular stores to the cell membrane [75]. Finally,
a few nonneuronal endogenous molecules have been also
identified as potential inductors of P2X4R in microglia,
namely, the proinflammatory cytokines INF-𝛾 [78], the mast
cell-derived tryptase activated PAR2 [79], and fibronectin,
a component of the extracellular matrix [80, 81]. At the
nuclear level, the interferon regulatory factor 8 (IRF8) has
been recently proposed as a key transcription factor involved
in the upregulation of P2X4Rs in activated microglia [82].
Once upregulated, P2X4Rs can efficiently respond to
extracellular fluctuation in ATP concentration and initiates
the intracellular cascade leading to BDNF synthesis and
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release. Being particularly highly Ca2+ permeable, P2X4
channels cause a significant Ca2+ influx and the downstream
activation of Ca2+-dependent intracellular pathways, among
which the phosphorylation of p38 MAP kinase, which is
directly involved in the synthesis and release of BDNF [67].
In addition Ca2+ influx through P2X4Rs is also necessary to
directly facilitate the release of BDNFby acting on the vesicle-
releasing machinery, which is typically an NSF-attachment
protein-(SNARE-) mediated exocytosis [67]. Alternative
pathways (i.e., ERK1/2) have been also suggested to promote
BDNF synthesis in culturedmicroglia [83, 84]; however, these
hypotheses need to be properly confirmed in vivo.
4. The Special Case of Neuropathic Pain
Based on the findings outlined above, the following con-
clusions can be drawn: (1) various extracellular signals may
activate microglia and upregulate P2X4Rs; (2) P2X4R activa-
tion triggers the release of BDNF from microglia; (3) BDNF-
TrKB signaling alters KCC2 function leading to a reduced
Cl− extrusion capacity which dampensGABAAR/GlyRmedi-
ated inhibition. Assuming that all these events happen in
sequence, one should expect that microglia, under certain
functional states, influence synaptic inhibition.This is indeed
the case of neuropathic pain [66]. Nociceptive transmis-
sion is normally conveyed to higher centers through spinal
nociceptive pathways. In the most simple configuration, this
involves peripheral neurons located in the dorsal root ganglia,
which contact second-order neurons in the spinal dorsal
horn, and a spinal projection neurons which transmits the
information to the thalamus. In the spinal dorsal horn, pain
transmission is controlled by a network of local inhibitory
interneurons which assure the separation of nociceptive
sensory pathways from nonnociceptive sensory pathways by
releasingGABA andGly [85]. Indeed, a spinal administration
of GABAAR or GlyR antagonists induces tactile allodynia
[86, 87], a clinical condition in which innocuous stimuli are
perceived as painful. Tactile allodynia is a classical symptom
of neuropathic pain and indicates an erroneous encoding
of low threshold stimuli through the nociceptive channel.
Several causal events have been postulated to promote spinal
disinhibition, including presynaptic mechanisms affecting
the amount of transmitter released and intracellular path-
ways regulating postsynaptic GABA and glycine receptor
function/expression [7]. In our laboratory, we found that
altered Cl− homeostasis in the superficial spinal dorsal horn
appears as a key mechanism underlying neuropathic pain
symptoms [88] and that this alteration results from the
release of BDNF from microglia [27]. Microglia had already
been implicated in the pathogenesis of neuropathic pain
[89–91], and in particular the upregulation of P2X4Rs in
microglia was early identified as a crucial step in the central
sensitization process [92]. P2X4Rs are in fact necessary for
the development of mechanical allodynia after nerve injury
and are required for the release of BDNF from microglia
[65, 67]. BDNF in turn binds TrkB receptors in neurons of the
superficial dorsal horn, thus compromising KCC2 function
and altering Cl− homeostasis [27]. Blocking the microglia-
to-neuron cascade at any level reverses established allody-
nia in neuropathic animals by restoring spinal inhibitory
GABAergic/glycinergic transmission [27, 28]. Subsequent
studies have provided additional evidence that this form
of spinal disinhibition happens in a different model of
pathological pain, such as spinal cord injury [93], diabetes-
induced neuropathy [94], and orofacial pain [95]. Moreover,
we have very recently shown that the pain hypersensitivity
induced by morphine (better known as morphine-induced
hyperalgesia) is mediated by the same P2X4Rs-BDNF-TrkB-
KCC2 cascade, thus recapitulating the sequence of events
described in neuropathic pain [28]. In the latter study, we
used a transgenic mouse in which BDNF expression was
genetically ablated in microglia only, and we showed that,
without microglial BDNF, morphine hyperalgesia does not
take place. The involvement of spinal microglia in this
specific form of hypersensitivity is due to the expression of
opioid receptors inmicroglia [84] whose activation promotes
P2X4Rs [28]. In turn, morphine appears to act on microglia
via a nonopioid receptor-dependent pathway to enable BDNF
release upon P2X4Rs activation [28].
In conclusion, ten years of investigations on the spinal
mechanisms of nociceptive transmission have provided com-
pelling evidence that neuropathic pain critically depends
on microglia-to-neuron signals which alter GABA/glycine-
mediated inhibition.
5. Microglia-BDNF-KCC2 Signaling in the
Pathogenesis of Multiple Neurological
Conditions
The microglia-to-neuron communication discovered in the
dorsal horn of the spinal cord can be virtually replicated in all
those regions of the CNSwhere functional TrkB receptors are
expressed andmay play a role in the development of multiple
central disorders [10]. Accumulating evidence in recent years
supports this hypothesis.
In the spinal motor system, a TrkB-KCC2 interaction has
been described in motoneurons following spinal cord injury
[21]. Here, the reduced Cl− extrusion capacity due to the
downregulation of KCC2 was associated with hyperreflexia
and spasticity, a clinical condition burdening a large number
of patients with spinal trauma [96].The authors did not inves-
tigated the origin of BDNF in their model; howevermicroglia
are clearly involved in the pathophysiology resulting from
spinal cord injury [97], and a role for microglial P2X4Rs has
also been envisaged [98], suggesting a microglial BDNF link.
In the brain, alterations in Cl− homeostasis have been
shown to underlay epilepsy in animals and humans [99].
Based on experiments in vitro on hippocampal slices [29,
30], TrkB-KCC2 signaling was proposed as the molecular
mechanism underlying hyperexcitability in epilepsy [30].
In this model, however, KCC2 downregulation was shown
to be activity dependent, thus implying a neuronal source
of BDNF whose release is directly related to the level of
network excitability. On the other hand, epilepsy has mul-
tiple etiologies and might develop in different brain areas.
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A role for microglia can be therefore predicted in those
pathological conditions which imply a neuronal damage
and the subsequent reorganization of synaptic function, as
in the case of a traumatic event [100]. Indeed, a TrkB-
dependent downregulation of KCC2 has also been described
in traumatic brain injury [101], a condition in which neuronal
death and inflammation clearly promote the activation of
microglia [102]. Interestingly, in animal models of traumatic
brain injury, microglia were found to express P2X4Rs and
phosphorylated p38 [103, 104], which is known to be themain
upstream signal for BDNF synthesis and release in microglia
[67].
Finally, a BDNF-mediated impairment of Cl− homeosta-
sis has been shown to underlie the central mechanisms of
opiate dependence in the ventral tegmental area (VTA) [52].
Although the main source of BDNF remains here elusive,
chronic exposure to opioids is known to activate microglia
and to induce the synthesis of BDNF [28, 84], which, in turn,
impairs Cl− homeostasis in central neurons [28]. In addition,
it has recently been described that functionalmodifications in
microglia are involved in mechanisms of opiate dependence
in the nucleus accumbens where the early exposure to
morphine in young rats was shown to influence drug-seeking
behavior in adulthood increasing the risk of drug-induced
reinstatement [105].
Taken together, these evidence indicate that BDNF-TrkB
signaling drives disinhibition by targeting KCC2 function.
Such an effect does not directly depend on the source of
BDNF (neuron, astrocytes, or microglia) but rather on the
intracellular pathways linking TrkB to KCC2 [29]. This is
exemplified in immature neurons where BDNF-TrkB signal-
ing, rather than causing KCC2 downregulation, stimulates
the synthesis of KCC2 and favors the developmental switch of
GABAergic transmission from excitatory to inhibitory [106].
In contrast, microglial BDNF has gained special attention
as underlying neurological diseases in adult tissue, and this
is mainly due to the specific role played by microglia in
the CNS. Indeed, microglia-driven disinhibition via BDNF-
TrkB signaling can be regarded as a peculiar consequence of
microglial reaction to injury or to certain pharmacological
treatments, potentially occurring in different areas of the
CNS. The “pathological” consequences of such process are
usually dramatic, leading for instance to an altered noci-
ceptive behavior or to seizure. It remains enigmatic what
the normal “physiological” meaning of the release of BDNF
frommicroglia and the subsequent downregulation of KCC2
is. The primary role of microglia is in fact to react in
response to a variety of external challenges supposedly with
the aim of protecting neurons. In this context, the release
of BDNF can be considered as a part of a neuroprotective
strategy, being neurotrophins classically involved in neuronal
survival process [107]. A neuroprotective and reparative role
for microglial BDNF has indeed been postulated during
the course of encephalitis [59], brain ischemia [62], and
traumatic injury [60]. Interestingly, the posttraumatic loss
of KCC2 in mature neurons induced by BDNF and the
subsequent GABA-mediated depolarization was found nec-
essary for neuronal survival of injured neurons, a mecha-
nism which is strongly reminiscent of the trophic effect of
excitatory GABA during CNS development [101]. In contrast,
the central inflammatory reaction in the spinal dorsal horn
following peripheral nerve injury appears to be substantially
maladaptive and detrimental. Indeed, the activation of spinal
microglia following nerve injury produces a release of BDNF
onto spinal neurons which are not directly injured. The main
effect of microglial activation in this case is thus the sup-
pression of spinal inhibition and the activation of nociceptive
pathways, leading to the clinical development of neuropathic
pain [27]. Microglia therefore appear as an ambiguous actor,
in some cases protective and in other cases having deleterious
actions [108]. An accurate prediction of the balance between
neuroprotection and neurotoxicity appears thus important to
understand how microglia intervene in diseases to develop
appropriate therapeutic strategies.
Yet, regardless of the positive or negative outcome
of microglia action on neuronal survival and repair, the
activation of the P2X4R-BDNF-TrkB-KCC2 cascade allows
microglia to critically control network excitability and to
unmask hiddenneuronal circuits that are normally kept silent
by the physiological Cl−-mediated inhibition (Figure 1) [109].
6. Future Directions
The signaling cascade described in this review represents
a molecular substrate underlying the mechanism by which
microglia target GABAergic/glycinergic neurotransmission.
However, it is likely that BDNF released from microglia
also challenge network excitability by mechanisms other
than KCC2. In particular, BDNF-TrkB signaling also targets
NMDA receptors [65, 110], and microglial BDNF has been
suggested to underlie certain forms of pathological pain via
the activation of spinal NMDA [111]. The outcome of both
KCC2 downregulation and NMDA potentiation is an overall
increase in network excitability. This raises the question of
whether modulations of KCC2 and NMDA functions are
independent processes or are reciprocally connected. Several
lines of evidence support the latter hypothesis [112, 113], and
future investigations are encouraged to further explore such
interactions in different neurological disorders. In addition to
BDNF,microglia are known to directly or indirectlymodulate
synaptic transmission through the release of tens of other
differentmolecules [114]. Most of past studies have differently
focused on the effect of these molecules in the modulation of
glutamatergic transmission. In this respect, a role has been
described for cytokines [115], glycine [116], NMDA receptor
agonists [117], adenosine [118], and ATP [119]. On the other
hand, a growing body of studies reported that cytokines
might also directly modulate GABAergic transmission [115]:
interleukin 1𝛽 was found to depress GABA release in a
model of autoimmune encephalitis [120] and to potentiate
GABAergic transmission in CA1 [121] or in hypothalamic
neurons [122]; both interleukin 6 and interleukin 1𝛽were seen
to reduce GABA- and Gly-mediated currents in the spinal
dorsal horn [123]; tumor necrosis factor 𝛼 was shown to
promote GABAAR endocytosis in hippocampal neurons thus
weakening the inhibitory synaptic strength [124]. In addition,
microglia also produce lipophilic gaseous molecules, such as
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Figure 1:Microglia control neuronal network excitability via secretion of BDNF.The left panel illustrates a schematic neuronal network in the
mature CNS under normal conditions: microglia (blue ramified cells) are in their resting state; small inhibitory interneurons release GABA
or Gly to repress the flow of signals across the network; normal KCC2 activity extrudes Cl− (black arrows) to maintain the Cl− gradient, and,
consequently, Cl− flows in through GABAAR/GlyR channels to inhibit activity. The right panel illustrates the same network after an external
event has inducedmicroglial activation (red cells) and the release ofmicroglial BDNF: BDNF-TrkB signaling causes downregulation of KCC2;
Cl− accumulates in neurons and the Cl− gradient collapses; GABAAR/GlyR-mediated inhibition is less effective in controlling neuronal firing,
and previously silent neuronal pathways are unmasked (yellow arrows).
nitric oxide [125–127], and lipidic inflammatory mediators,
such as prostaglandins [127, 128]. Interestingly, prostaglandin
E2 directly suppresses glycine-mediated transmission in the
spinal dorsal horn, a mechanism centrally involved in the
development of inflammatory pain [129, 130]. Deeper insights
into the role played by each of these messengers in normal
and pathological conditions are required to improve our
understanding of the role of microglia-to-neuron communi-
cation.
Yet, the effects reported in different studies for most of
these microglia-derived molecules are often quite dissimilar
and critically influenced by the experimental paradigms,
drug concentrations, and neuronal populations considered
[114]. In addition, the mechanisms leading to the release
of specific molecules, as well as the molecular pathways
activated in neurons, are still poorly understood, making it
difficult to draw a coherent picture for their role in synap-
tic transmission. Conversely, the P2X4R-BDNF-TrkB-KCC2
cascade described here appears to connect altered extracellu-
lar conditionswithmicroglia activation, neuronal excitability,
and eventually the development of a pathological behavior.
Collectively, these findings open new important therapeutic
avenues for the control of neuropathic pain [25] and epilepsy
[99]. Yet, many questions are left unanswered and need to
be addressed to better delineate the range of applications
for an effective microglia-targeted therapeutic strategy; in
particular: which neurological disorders are associated with a
microglia-driven loss of inhibition? In which brain areas? Do
allmicroglia have the same potential to synthesize and release
BDNF when exposed to a given extracellular challenge?
Or, instead, are microglia a heterogeneous population with
multiple phenotypes playing different roles in different CNS
areas and in different pathological states?
Tackling the multiform universe of microglia-neuron
interactions and understanding the underlying molecular
pathways offer the opportunity to identify specific biomarkers
for neurological disorders and potential targets for novel
therapeutic approaches.
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